Disease Overviews
One autoimmune pathway. Two related diseases.
Graves’ disease (GD) and thyroid eye disease (TED) share the same causal disease driver – thyroid stimulating autoantibodies (TSAbs) to the Thyroid Stimulating Hormone Receptor (TSHR).
Despite this shared root cause, today there are no approved therapies that address both conditions.
Disease Overviews
One autoimmune pathway. Two related diseases.
Graves’ disease (GD) and thyroid eye disease (TED) share the same causal disease driver – thyroid stimulating autoantibodies (TSAbs) to the Thyroid Stimulating Hormone Receptor (TSHR).
Despite this shared root cause, today there are no approved therapies that address both conditions.
Graves’ Disease (GD)
Graves’ Disease (GD)
GD affects >1% of the population. Excess thyroid hormone can have adverse impacts throughout the body and significantly affects quality of life. Common symptoms include rapid heartbeat (tachycardia), tremors, muscle weakness, enlarged thyroid (goiter), and unintended weight loss. Approximately half of GD patients develop TED.
Today, treatment options for GD are limited. Current medications do not address the causal disease process, carry risks of serious side effects, and are associated with high rates of relapse. Many patients undergo permanent removal of their thyroid. Importantly, existing therapies for GD do not treat or prevent TED.
GD affects >1% of the population. Excess thyroid hormone can have adverse impacts throughout the body and significantly affects quality of life. Common symptoms include rapid heartbeat (tachycardia), tremors, muscle weakness, enlarged thyroid (goiter), and unintended weight loss. Approximately half of GD patients develop TED.
Today, treatment options for GD are limited. Current medications do not address the causal disease process, carry risks of serious side effects, and are associated with high rates of relapse. Many patients undergo permanent removal of their thyroid. Importantly, existing therapies for GD do not treat or prevent TED.
Thyroid Eye Disease (TED)
Thyroid Eye Disease (TED)
TED is a disfiguring and potentially vision-threatening condition, closely related to GD. Nearly all patients with TED have coexisting hyperthyroidism due to GD. Clinical manifestations range from eye irritation and redness in milder cases, to inflammation, eye bulging (proptosis), double vision (diplopia), eyelid retraction, pain, and potentially vision loss.
Current medications do not address the causal disease process, have burdensome regimens and side effects, and frequently result in relapse. Surgical interventions may be considered for certain patients but are highly invasive and carry procedural risks.
TED is a disfiguring and potentially vision-threatening condition, closely related to GD. Nearly all patients with TED have coexisting hyperthyroidism due to GD. Clinical manifestations range from eye irritation and redness in milder cases, to inflammation, eye bulging (proptosis), double vision (diplopia), eyelid retraction, pain, and potentially vision loss.
Current medications do not address the causal disease process, have burdensome regimens and side effects, and frequently result in relapse. Surgical interventions may be considered for certain patients but are highly invasive and carry procedural risks.
